newsfilter
← Latest News
GlobeNewswire·

Sensei Biotherapeutics Reports First Quarter 2025 Financial Results and Updates on Clinical Progress

- Favorable clinical data in PD-(L)1 resistant patients - - Dose expansion enrollment complete with full data expected by year-end 2025 - - Cash runway into the second quarter of 2026 - BOSTON, May 06, 2025 (GLOBE